Experienced in Leukemia
Experienced in Leukemia
101 Manning Dr, 
Chapel Hill, NC 

Overview

Stuart Gold is a Pediatric Hematologist Oncology provider in Chapel Hill, North Carolina. Dr. Gold is rated as an Experienced provider by MediFind in the treatment of Leukemia. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Ewing Sarcoma, Adult Soft Tissue Sarcoma, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 23 peer reviewed articles and participating in 49 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles and participated in 17 clinical trials in the study of Leukemia.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in NC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

101 Manning Dr, Chapel Hill, NC 27599

Additional Areas of Focus

Dr. Gold has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


49 Clinical Trials

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Renal Tumors Classification, Biology, and Banking Study
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
View 42 Less Clinical Trials
Similar Doctors
Advanced in Leukemia
Pediatric Hematology Oncology
Advanced in Leukemia
Pediatric Hematology Oncology
1514 Cumberland Rd, 
Chapel Hill, NC 
 (4.3 miles away)
Languages Spoken:
English
Offers Telehealth

Paul Martin is a Pediatric Hematologist Oncology provider in Chapel Hill, North Carolina. Dr. Martin is rated as an Advanced provider by MediFind in the treatment of Leukemia. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Infantile Neutropenia, Graft Versus Host Disease (GvHD), and Bone Marrow Transplant.

Kris M. Mahadeo
Advanced in Leukemia
Pediatric Hematology Oncology | Pediatrics
Advanced in Leukemia
Pediatric Hematology Oncology | Pediatrics

Duke Children's Health Center Bone Marrow Transplant Clinic

2301 Erwin Rd, 
Durham, NC 
 (9.6 miles away)
Experience:
16+ years
Languages Spoken:
English

I care for patients and families seeking bone marrow transplants, cellular therapies, and gene therapies for high-risk cancers, genetic and metabolic disorders, and primary immune deficiencies. I work closely with a comprehensive team to ensure the best long-term outcomes and quality of life. I am attentive to the needs of my patients, as well as their caregivers and families. In my spare time, I enjoy traveling and exploring new cultures. Dr. Mahadeo is rated as an Advanced provider by MediFind in the treatment of Leukemia. His top areas of expertise are Hepatic Venoocclusive Disease with Immunodeficiency, Leukemia, Infantile Neutropenia, Bone Marrow Transplant, and Tissue Biopsy.

Experienced in Leukemia
Pediatric Hematology Oncology
Experienced in Leukemia
Pediatric Hematology Oncology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (0.1 miles away)
Languages Spoken:
English

Andrew Smitherman is a Pediatric Hematologist Oncology provider in Chapel Hill, North Carolina. Dr. Smitherman is rated as an Experienced provider by MediFind in the treatment of Leukemia. His top areas of expertise are Leukemia, Acute Lymphoblastic Leukemia (ALL), Mesenteric Venous Thrombosis, and Hemolytic Anemia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gold's expertise for a condition
ConditionClose
        View All 25 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile